A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

The world’s first dedicated hypotony clinic, funded by Moorfields Eye Charity, has been established at the Moorfields Eye ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

The treatment with what is thought of as a common medical supply has shown positive results in the patients who have received ...

New ‘filler’ treatment brings hope to people left blind by rare condition - Specialists injected the eyes of hypotony ...

Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given ...

People with a rare and untreatable condition that causes blindness have had their sight restored with injections of a ...

Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...